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ABSTRACT 
Background 
Bipolar disorder (BD) is a common and highly heritable disorder of mood. Genome-wide 
association studies (GWAS) have identified several independent susceptibility loci. In 
order to extract more biological information from GWAS data, multi-locus approaches 
represent powerful tools since they utilize knowledge about biological processes to 
integrate functional sets of genes at strongly to moderately associated loci.  
 
Methods 
We conducted gene set enrichment analyses (GSEA) using 2.3 million single-nucleotide 
polymorphisms, 397 Reactome pathways and 24,025 patients with BD and controls. 
RNA expression of implicated individual genes and gene sets were examined in post-
mortem brains across lifespan. 
Results 
Two pathways showed a significant enrichment after correction for multiple 
comparisons in the GSEA: GRB2 events in ERBB2 signaling, for which 6 of 21 genes 
were BD associated (PFDR=0.0377), and NCAM signaling for neurite out-growth, for 
which 11 out of 62 genes were BD associated (PFDR=0.0451). Most pathway genes 
showed peaks of RNA co-expression during fetal development and infancy and mapped 
to neocortical areas and parts of the limbic system. 
Limitations 
Pathway associations were technically reproduced by two methods, although they were 
not formally replicated in independent samples. Gene expression was explored in 
controls but not in patients.  
 
Conclusions 
Pathway analysis in large GWAS data of BD and follow-up of gene expression patterns 
in healthy brains provide support for an involvement of neurodevelopmental processes 
in the etiology of this neuropsychiatric disease. Future studies are required to further 
evaluate the relevance of the implicated genes on pathway functioning and clinical 
aspects of BD. 
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INTRODUCTION 
Bipolar disorder (BD) is a genetically complex mental illness. During the past ten years, 
several genome-wide association studies (GWAS) of BD were conducted and have 
identified 19 loci harboring common genetic susceptibility variants (Sullivan et al., 
2017). It is assumed that with growing sample sizes the number of loci will increase, as 
has been successfully demonstrated for schizophrenia, where GWAS in 61,000 patients 
found 155 independent loci (Sullivan et al., 2017).  
Gene set enrichment analysis (GSEA) is a powerful tool to retrieve more biological 
information from existing GWAS. Such multi-locus approaches utilize functional 
frameworks of ontologies or pathways to integrate genes at strongly to moderately 
associated loci. Using the same sample size, GSEA therefore has greater statistical 
power to detect a polygenic contribution of individually small effects to overall risk than 
single-locus analyses (Lee et al., 2012).  
Here, we applied GSEA algorithms to a large published GWAS on BD, including 
approximately 9,700 patients and 14,200 controls (Mühleisen et al., 2014). We found 
associations between BD and two signaling pathways involved in brain development. 
 
METHODS AND MATERIALS 
Phenotype and SNP Data  
For GSEA, we used combined data from the Systematic Investigation of the Molecular 
Causes of Major Mood Disorders and Schizophrenia (MooDS) and Psychiatric 
Genomics Consortium (PGC) consortia comprising 2,267,487 autosomal single-
nucleotide polymorphisms (SNPs) from 9,747 patients with life-time diagnoses of BD 
and 14,278 controls, as described by Mühleisen et al. (2014). Written informed consent 
was obtained from all patients and controls before participation in the study.  
Gene Set Enrichment Analyses 
For discovery, we used Meta-Analysis Gene-set Enrichment of variaNT Associations 
(MAGENTA; (Segrè et al., 2010)) with its default settings. At genome-wide level, each 
gene was mapped to the GWAS SNP showing the lowest p-value within gene 
boundaries (RefSeq definitions), to minimize the effect of a potential confounding factor 
introduced by overlapping gene boundaries (Sedeño-Cortés and Pavlidis, 2014). P-
values of these index SNPs were corrected for confounders such as gene size, SNP 
density and linkage disequilibrium-related properties in the stepwise multiple linear 
regression model of MAGENTA. Resulting gene scores were assigned to target gene 
sets. For each target gene set, the observed number of gene scores above the user-
defined threshold (here 95%) is evaluated against the expected number of gene scores 
above this threshold for gene sets of identical size, randomly sampled from the genome 
multiple times. A non-parametric test produces the nominal p-value for each tested 
target gene set. False-discovery rate (FDR) was used to correct for multiple testing 
(PFDR). 
For secondary analysis of the significantly enriched pathways, we applied Gene Set 
Analysis SNP (GSA-SNP; (Nam et al., 2010)) on the same input data. GSA-SNP uses 
p-values of SNPs to calculate enrichment scores by using the Z-statistic method. But 
instead of using the maximum effect per gene as a proxy for the respective gene, we 
chose the second-best p-value to represent the effect of each gene to avoid spurious 
associations (Kwon et al., 2012). 
For pathways, we used curated target gene sets (pathways) from Reactome as 
available through the Molecular Signature Database (v6.0; (Subramanian et al., 2005). 
Their sizes were restricted from 20 to 200 to avoid overly narrow or broad gene sets. 
This resulted in 397 sets for GSEA.  
Gene expression data  
BrainScope enables interactive visual exploration of spatial and temporal human brain 
transcriptomes from the Allen Institute for Brain Science (Huisman et al., 2017). Here 
we focused on the dataset Developmental Transcriptome from the BrainSpan atlas that 
had been pre-processed and re-analyzed by BrainScope’s developers resulting in the 
dataset Developing human (comparative explorer) with RNA expression levels of 
18,233 genes (Entrez Gene definitions) that were z-score normalized, to have a zero 
mean and a standard deviation of 1. 
 
To explore changes of co-expressed genes in brain regions and time windows, we used 
heat maps of the comparative explorer from BrainScope under default settings. Each 
square of a heat map displayed the average regional expression of the selected gene(s) 
across pooled tissue samples (replicates, developmental stages) from donor brains 
(controls). For BD-associated pathways from GSEA results, heat maps were assembled 
and annotated using standard graphical software. The brain regions covered neocortical 
areas including primary cortices (auditory, motor, somatosensory, visual), pre- and 
orbitofrontal cortices, the temporal cortex (inferolateral, posterior superior), the parietal 
cortex (posteroventral); principal structures of the diencephalon including parts of the 
basal ganglia (amygdala, striatum) and limbic system (anterior cingulate, amygdala, 
hippocampus) coiled around and connected to thalamus and hypothalamus; the 
hindbrain (cerebellar cortex). The time windows comprised fetal development (from 
early 2nd trimester to birth), infancy (from birth to one year), childhood (from two to 
eleven years), adolescence (from 13 to 19 years), and adulthood (from 21 to 40 years). 
BrainScope, BrainSpan, and Entrez Gene are publicly accessible at www.brainscope.nl,  
www.brainspan.org, and www.ncbi.nlm.nih.gov/gene. 
 
RESULTS 
Discovery and validation of BD-associated pathways 
GSEA by MAGENTA on MooDS-PGC data revealed two study-wide significant 
Reactome pathways when applying the significance criterion of FDR < 0.05 (Table 1). 
The best finding was GRB2 events in ERBB2 signaling (PFDR=0.0377), for which 6 
genes were associated (NRAS, KRAS, EGFR, ERBB2, MAPK1, HBEGF) out of 21 in 
the pathway. The second finding was NCAM signaling for neurite out-growth 
(PFDR=0.0451) for which 11 of 62 genes were associated (NCAN, SPTBN2, FYN, 
NRAS, CREB1, KRAS, CACNB3, COL2A1, CACNB2, MAPK1, SPTBN1). Three 
significant genes were common to both pathways (NRAS, KRAS, MAPK1). The 
associated genes showed a balanced contribution to the total significance of the two 
target gene sets (Supplementary Table 1). The subsequent GSEA by GSA-SNP on 
the same input data validated the enrichments in the two target gene sets (P=4.80E-06 
and P=3.28E-08, respectively; Table 1). 
Exploration of gene expression in BD-associated pathways 
To assess patterns of co-expressed genes from both pathways in the developing and 
adult brain, we used data from BrainSpan accessed through BrainScope and screened 
(i) expression of each single associated gene, (ii) expression of the combined set of 
associated genes (Combined), and (iii) expression of associated genes in context of 
target gene sets (Whole pathway). We found that five of the six genes enriched in 
GRB2 events in ERBB2 signaling demonstrated expression peaks during fetal 
development and infancy, while MAPK1 expression was lower during prenatal stages 
and higher during postnatal stages. The combined pattern of the six genes emphasized 
neural development and was similar to the whole pathway pattern. In NCAM signaling 
for neurite out-growth, four of the ten enriched genes (NCAN, FYN, NRAS, CREB1) 
revealed high expression during fetal and early postnatal development. CACNB2, 
MAPK1, SPTBN1, and SPTBN2 showed low expression during fetal stages but 
increased later on, especially in infancy. Overall, most genes showed peaks of co-
expression during fetal development (early second to third trimester) and infancy (birth 
to 18 months) in many neocortical areas and parts of the limbic system. Spatio-temporal 
expression patterns of genes stratified by pathway are displayed in Figure 1. 
 
DISCUSSION 
Current disease models of BD suggest a multifactorial etiology resulting from the 
additive effects of many gene variants at different loci together with the effect of 
environmental factors. GWAS have demonstrated that the genotype relative risks of the 
involved common susceptibility variants are small and that large sample sizes are 
necessary to achieve sufficient statistical power to identify them (Sullivan et al., 2017). 
In the present analysis, we chose to apply GSEA to our GWAS data because this 
approach should have greater statistical power to detect a polygenic contribution of 
individually small effects to overall risk than single-locus analyses (Lee et al., 2012). To 
further strengthen our findings, we investigated genes within the implicated pathways 
for expression at milestones of normal brain development to obtain information on their 
relevance during ontogenetic stages. Biological pathway studies of BD so far have 
found evidence for genes involved in calcium channels, hormonal regulation, glutamate 
signaling, neural development, and histone methylation (Nurnberger et al., 2014; 
O'Dushlaine et al., 2015).  
Our strongest finding was GRB2 events in ERBB2 signaling which functions to promote 
cell proliferation, survival, and differentiation, not only in the brain. Biologically, an 
association with ERBB2, EGFR, and HBEGF is plausible because they form a ligand-
activated receptor complex for signaling and thus seem to be key players of that 
pathway. The importance of ERBB2 in BD is further supported by a genome-wide 
significant association finding (Hou et al., 2016) and by the observation of dysregulated 
ERBB2 expression in the dorsolateral prefrontal cortex in both BD and schizophrenia 
(Shao and Vawter, 2008). This expression alteration is significantly related to lifetime 
antipsychotic exposure, supporting ERBB2 as target for clinical research. ErbB2/B4-
deficient mice exhibit elevated aggression and reduced prepulse inhibition that both can 
be rescued by clozapine treatment, a frequently used antipsychotic medication (Barros 
et al., 2009). EGFR (alias ERBB1) is reported to play an essential role in axon 
myelination during the first postnatal weeks and can therefore be considered as an 
important regulator of neurodevelopment (Aguirre et al., 2007). The gene was also 
supported by single SNP and haplotype analysis in a GWAS of BD (Sklar et al., 2008). 
HBEGF is a EGF-like binding partner of EGFR and mice lacking Hb-egf in the ventral 
forebrain showed abnormalities in psychomotor behavior and neurotransmission which 
can be ameliorated by typical or atypical antipsychotics (Oyagi et al., 2009).  
Our second finding was NCAM signaling for neurite out-growth which modulates neural 
differentiation and synaptic plasticity. Homophilic binding of NCAM1 molecules at the 
cell-surface induces signaling that leads to cell-cell adhesion and axon elongation. 
Association with NCAN in this pathway is of major importance since experiments in rats 
have demonstrated that interference of Ncam1-Ncam1 bindings by concurrent Ncan 
inhibits these cellular processes (Retzler et al., 1996). NCAN encodes an extracellular 
matrix proteoglycan and has been described as important susceptibility gene for BD 
(Cichon et al., 2011). Furthermore, NCAN was reported to be associated with brain 
development in health and disease, specifically to gray matter loss in central limbic 
regions and higher folding in the lateral occipital and prefrontal cortex suggesting 
impairments of emotion perception and regulation and top-down cognitive functioning 
(Dannlowski et al., 2015). Behavioral abnormalities in Ncan-deficient mice show striking 
similarities with mania symptoms in humans that can be rescued by lithium treatment, 
an established mood stabilizer (Miró et al., 2012). Association with CACNB2 and 
CACNB3 represents another highlight of this pathway, since abnormal calcium channel 
activity is considered to be important for BD (Nurnberger et al., 2014). Unexpectedly, 
CACNA1C was not found among enriched pathway genes, despite strong support of 
this gene from SNP data. Further evaluation revealed that CACNA1C was absent from 
the pathway definition. A possible link to our other finding exists through a gene overlap 
of KRAS, NRAS and MAPK1 as well as binding between NCAM1 and EGFR. 
In both pathways, most genes showed high co-expression during fetal development and 
infancy in many neocortical and subcortical areas indicating co-expression and possibly 
co-working of encoded protein functions. These observations provide links to brain 
regions where known pathophysiological changes in BD patients occur, for instance, in 
the limbic system which is concerned with many aspects of emotion and behavior. 
Limitations 
Although both pathway findings were technically reproduced by two different 
approaches and are based on one of the largest GWAS data of BD so far, association 
replication in independent samples was not attempted. Gene expression was explored 
in control brains only, which may show co-expression differences compared with BD 
brains. Follow-up studies are required to further evaluate the relevance of our findings 
for etiological and clinical aspects of BD. 
Conclusion 
The present study found evidence for associations between BD and two signaling 
pathways. Integration of evidence from genetic studies, brain developmental expression 
patterns and molecular functions of these pathways support the hypothesis that 
neurodevelopmental processes play an important role in the etiology of BD.  
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TABLES AND FIGURES 
Figure 1 Expression patterns of genes in BD-associated pathways during normal 
brain development. Each square of a heat map displays the spatio-temporal 
expression of the selected gene(s) in the indicated regions and stages in control brains. 
Levels of RNA expression are z-score normalized ranging from blue (low) over white 
(zero mean) to red (high). Patterns are shown for single enriched genes (gene 
symbols), the combined set of enriched genes (combined), and the target gene set 
(whole pathway). ERBB2 is a member of the EGF receptor family. Since ERBB2 has no 
ligand-binding domain, it needs a co-receptor to become activated. Upon binding of an 
EGF ligand, the ERBB2-EGFR heterodimer recruits adaptor protein GRB2 leading to 
SOS1-mediated guanine-nucleotide exchange on RAS (KRAS, NRAS) and activation of 
RAF and the MAP kinase cascade (MAPK1). NCAM1 works on modulation of 
intracellular signaling, either by activation of FGF receptors or cytoplasmic tyrosine 
kinases (FYN) that initiate MAP kinase cascades (MAPK1) and a transcription factor 
(CREB1) which regulates expression of genes for growth and survival of neurites. 
Spectrins (SPTBN1, SPTBN2) are cytoskeletal molecules and manage to link RPTP-
alpha to the cytoplasmic domain of NCAM1. L-type channels (CACNB2, CACNB3) 
associate with NCAM1 in growth cones at the sites of NCAM1 clusters leading to 
processes that promote neurite out-growth. 
 
 
Table 1 Association results of the GSEA. MAGENTA and GSA-SNP were used for 
discovery and validation steps.  
  
 
MAGENTA, 95th percentile enrichment cutoff 
GSA-SNP, 
2
nd
 best SNP 
Gene set 
name 
Gene set 
identifier 
N 
genes 
PFDR Sign. genes (gene p-value) 
Empirical 
p-value 
GRB2 events 
in ERBB2 
signaling 
R-HSA-
1963640 
21 0.0377 NRAS (1.94E-03), KRAS (2.20E-03), 
EGFR (6.18E-03), ERBB2 (0.0196), 
MAPK1 (0.0222), HBEGF (0.0306) 
4.80E-06 
NCAM 
signaling for 
neurite out-
growth 
R-HSA-
375165 
62 0.0451 NCAN (1.40E-05), SPTBN2 (6.64E-05), 
FYN (2.75E-04), NRAS (1.94E-03), CREB1 
(2.11E-03), KRAS (2.20E-03), CACNB3 
(4.86E-03), COL2A1 (0.0127), CACNB2 
(0.0138), MAPK1 (0.0222), SPTBN1 
(0.0251) 
3.28E-08 
Abbreviations: CACNB2, calcium voltage-gated channel auxiliary subunit beta 2; CACNB3, calcium 
voltage-gated channel auxiliary subunit beta 3; COL2A1, collagen type II alpha 1 chain; CREB1, cAMP 
responsive element binding protein 1; EGF, epidermal growth factor; EGFR, EGF receptor; ERBB2, Erb-
B2 receptor tyrosine kinase 2; FYN, FYN proto-oncogene; GRB2, Growth factor receptor-bound protein 2; 
HBEGF, heparin-binding EGF-like growth factor; KRAS, KRAS proto-oncogene, GTPase; MAPK1, 
mitogen-activated protein kinase 1; N, number; NCAM1, neural cell adhesion molecule 1; NCAN, 
neurocan; NRAS, neuroblastoma RAS Viral oncogene homolog; PFDR, FDR-adjusted p-value; SPTBN1, 
spectrin beta, non-erythrocytic 1; SPTBN2, spectrin beta, non-erythrocytic 2. 
 
Supplementary Table 1 Study-wide significant pathway results identified in 
MAGENTA. 
Abbreviations: Chr, cytogenetic band of the chromosome; kb, kilobases; * MAGENTA-
based gene P value; † GWAS-based results. 
 
Highlights 
 ERBB2, EGFR, and HBEGF associations indicate a ligand-receptor complex for 
signaling 
 NCAN association suggests disturbance of NCAM1 signaling for axon elongation 
 Most genes showed high co-expression during neurodevelopment in BD-related 
brain regions. 
